Contains Nonbinding Recommendations

**Guidance on Mefloquine Hydrochloride**

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Mefloquine Hydrochloride

**Form/Route:** Tablets/Oral

**Recommended studies:** 1 study

Type of study: Fed Design: Single-dose, parallel design in-vivo Strength: 250 mg Subjects: Normal healthy males and females, general population. Additional Comments: Mefloquine has been shown to cause esophagitis/gastritis when administered under fasting conditions. A fasting bioequivalence study is not recommended.

---

**Analytes to measure:** Mefloquine in plasma

**Bioequivalence based on (90% CI):** Mefloquine

**Waiver request of in-vivo testing:** Not Applicable

**Dissolution test method and sampling times:**

Please note that a Dissolution Methods Database is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

*Finalized May 2008*